AbbVie added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies. The company jointly developed and markets Imbruvica with J&J's Janssen.

AbbVie Adds its Top-Selling Cancer Drug Imbruvica to its 340B Contract Pharmacy Restrictions

Drug manufacturer AbbVie had added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies, effective April 1.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report